★
BSX
Boston Scientific Corp · Health Care
FCF$3.5bB
Rev+26.0%A-
D/E0.47B+
P/E24.1xB
PEG0.93B+
85Score
$57.781Y Target$62.40Near-term target
5Y Target$77.32Compound horizon
10Y Target$98.70Long-dated conviction
FCF$3.5bTTM · 03/26B
FCF $3.5b — solid, comfortably covers operations and capital return · TTM computed from 4 most-recent quarters (TTM · 03/26).
Rev+26.0%TTM YoYA-
Revenue +26.0% — strong growth, well above S&P median (~7%) · TTM YoY from trailing-4-quarter revenue sum vs prior 4 quarters.
D/E0.47totalB+
D/E 0.47 — healthy leverage, well below danger zone · Total D/E computed from balance sheet (short-term + long-term debt + lease obligations) ÷ stockholders equity. More accurate than native field, which often uses long-term debt only.
P/E24.1xB
P/E 24.1 — moderate premium, defensible with growth
PEG0.93proxyB+
PEG 0.93 — near fair value, classic Lynch benchmark (1.0) · PEG proxy: P/E ÷ revenue growth % (true PEG requires forward EPS estimates, not in Finnhub free tier).
Why now
Health Care · market cap $85.9b. Down 47% from 52-week high of $109.50 — deep drawdown territory. Revenue growing +26% — in hypergrowth territory. PEG 0.93 — paying under fair value for the growth rate.
Moat
Net margin 17% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 15% meets the long-run market sustainable threshold — solid but not differentiated; the durability comes from elsewhere. $85.9b market cap gives the company enough scale to absorb fixed costs that subscale competitors can't, without yet being so large that growth has to come from acquisition.
Risk
Down 47% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
Horizon
1-3 yr $62.40 (structural (no analyst coverage)) — multiple re-rating thesis requires a catalyst. 5 yr $77.32 at ~6% CAGR — dividend + buyback compounding. 10 yr $98.70 if the moat survives secular pressure.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Position sizing · BSX
Shares to buy
34
Position size
$1,965
3.9% of portfolio
Stop price
$43.34
25% below $57.78
$ at risk
$500.00
1% of portfolio
Math only — share count is floor(portfolio × risk% ÷ (price × stop%)). Doesn't account for commissions, slippage, gap risk, or position-correlation across your book. Inputs persist locally; never sent to the server. Not investment advice.